In the present study, we investigated the in vitro inhibitory effects of combination therapy with HDAC inhibitor and PI3K inhibitor against breast cancer cell line (MCF-7), as well as associated mechanisms to provide the scientific rationale for clinical application in the treatment of breast cancer. This evidence concerns the gene HDAC9 and breast carcinoma.